--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-25-018512" form_type: "8-K" ticker: "ASBP" cik: "0001847345" company_name: "Aspire Biopharma Holdings, Inc." filed_at: "2025-10-17T23:59:59+00:00" generated_at: "2026-05-17T03:25:40.482817+00:00" event_type: "regulatory" sentiment: "negative" materiality_score: 0.85 calibrated_materiality_score: 0.85 confidence: "high" source: SEC EDGAR --- # Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals ## Summary - On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum). - The Company failed to regain compliance within the 180-day period that ended on October 13, 2025. - The Company requested a hearing before the Nasdaq Hearings Panel and paid a $20,000 fee, which stays the suspension pending the Panel's decision. - The Company will present a plan to regain compliance and may request an extension of up to 180 additional days. - There is no assurance that the Panel will grant continued listing or that compliance can be regained. ## SEC filing metadata - accession: 0001493152-25-018512 - form_type: 8-K - ticker: ASBP - cik: 0001847345 - company_name: Aspire Biopharma Holdings, Inc. - filed_at: 2025-10-17T23:59:59+00:00 - event_type: regulatory - sentiment: negative - materiality_score: 0.85 - calibrated_materiality_score: 0.85 - confidence: high - sec_items: 3.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-25-018512 - JSON: https://secwatch.observer/filing/0001493152-25-018512.json - Plain text: https://secwatch.observer/filing/0001493152-25-018512.txt ## Key facts - Listing & Compliance Notices Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)). - Exchange: nasdaq - Notice: deficiency notice - Deficiency: market value - Rules: 5450(b)(2)(A) source text: April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”) received two letters from the Listing Qualifications Staff (“Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified the Company of a deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000 (the “MVLS Rule”). The deficiency evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm - Listing & Compliance Notices Aspire Biopharma Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)). - Exchange: nasdaq - Notice: deficiency notice - Deficiency: minimum bid price - Rules: 5450(a)(1) source text: April 16, 2025, Aspire Biopharma Holdings, Inc. (the “Company”) received two letters from the Listing Qualifications Staff (“Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”), each addressing a separate compliance deficiency under the Nasdaq Listing Rules. The first letter notified the Company of a deficiency with regard to Rule 5450(b)(2)(A) (the “MVLS Notice”), which requires a company, whose securities are listed on The Nasdaq Global Market under the “Market Value Standard”, to maintain a minimum Market Value of Listed Securities (an “MVLS”) of $50,000,000 (the “MVLS Rule”). The deficiency evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm - Listing & Compliance Notices Aspire Biopharma Holdings, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)). - Exchange: nasdaq - Notice: delisting notice - Deficiency: market value - Rules: 5450(b)(2)(A), 5810(c)(3)(C) source text: October 15, 2025, (the “October Letter”) the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely appeals the Staff’s determination and requests a hearing before the Nasdaq Hearings Panel (the “Panel”). Both items of noncompliance serve as an independent basis for delisting the Company’s securities from Nasdaq. The Company has requested a hearing before the Panel and has paid the associated fee of $20,000, which has stayed the suspension of the Company’s Common Stock and publicly traded Warrants pending the Panel’s decision. At the hear evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm - Listing & Compliance Notices Aspire Biopharma Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)). - Exchange: nasdaq - Notice: delisting notice - Deficiency: minimum bid price - Rules: 5450(a)(1), 5810(c)(3)(A) source text: October 15, 2025, (the “October Letter”) the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely appeals the Staff’s determination and requests a hearing before the Nasdaq Hearings Panel (the “Panel”). Both items of noncompliance serve as an independent basis for delisting the Company’s securities from Nasdaq. The Company has requested a hearing before the Panel and has paid the associated fee of $20,000, which has stayed the suspension of the Company’s Common Stock and publicly traded Warrants pending the Panel’s decision. At the hear evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.